EA201991195A1 - MULTI-DIMENSIONAL POLYPEPTIDES MODULATING T-CELLS AND WAYS OF THEIR APPLICATION - Google Patents

MULTI-DIMENSIONAL POLYPEPTIDES MODULATING T-CELLS AND WAYS OF THEIR APPLICATION

Info

Publication number
EA201991195A1
EA201991195A1 EA201991195A EA201991195A EA201991195A1 EA 201991195 A1 EA201991195 A1 EA 201991195A1 EA 201991195 A EA201991195 A EA 201991195A EA 201991195 A EA201991195 A EA 201991195A EA 201991195 A1 EA201991195 A1 EA 201991195A1
Authority
EA
Eurasian Patent Office
Prior art keywords
polypeptides
multimeric
modulating
cells
relates
Prior art date
Application number
EA201991195A
Other languages
Russian (ru)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/067663 external-priority patent/WO2018119114A1/en
Publication of EA201991195A1 publication Critical patent/EA201991195A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Данное изобретение относится к вариантным иммуномодуляторным полипептидам и гибридным полипептидам, содержащим вариантные иммуномодулирующие пептиды. Данное изобретение относится к мультимерным полипептидам, модулирующим T-клетки, и к композициям, содержащим их, в которых указанные мультимерные полипептиды, модулирующие T-клетки, содержат вариантный иммуномодуляторный полипептид по данному изобретению. Данное изобретение относится к нуклеиновым кислотам, содержащим нуклеотидные последовательности, кодирующие мультимерные полипептиды, модулирующие T-клетки, и к клеткам-хозяевам, содержащим указанные нуклеиновые кислоты. Данное раскрытие предоставляет способы модулирования активности T-клетки; указанные способы включают контактирование T-клетки с мультимерным полипептидом, модулирующим T-клетки, по данному изобретению.This invention relates to variant immunomodulatory polypeptides and hybrid polypeptides containing variant immunomodulating peptides. This invention relates to multimeric T cell modulating polypeptides and compositions comprising them, wherein said multimeric T cell modulating polypeptides comprise a variant immunomodulatory polypeptide of the invention. This invention relates to nucleic acids containing nucleotide sequences encoding multimeric T-cell modulating polypeptides, and to host cells containing said nucleic acids. This disclosure provides methods for modulating T cell activity; these methods include contacting the T cells with the multimeric T cell modulating polypeptide of the invention.

EA201991195A 2017-11-06 2017-12-20 MULTI-DIMENSIONAL POLYPEPTIDES MODULATING T-CELLS AND WAYS OF THEIR APPLICATION EA201991195A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762582132P 2017-11-06 2017-11-06
PCT/US2017/067663 WO2018119114A1 (en) 2016-12-22 2017-12-20 T-cell modulatory multimeric polypeptides and methods of use thereof

Publications (1)

Publication Number Publication Date
EA201991195A1 true EA201991195A1 (en) 2019-11-29

Family

ID=68653633

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991195A EA201991195A1 (en) 2017-11-06 2017-12-20 MULTI-DIMENSIONAL POLYPEPTIDES MODULATING T-CELLS AND WAYS OF THEIR APPLICATION

Country Status (1)

Country Link
EA (1) EA201991195A1 (en)

Similar Documents

Publication Publication Date Title
PH12019501413A1 (en) T-cell modulatory multimeric polypeptides and method of use thereof
AU2017266905A1 (en) Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
WO2017151818A3 (en) T-cell modulatory multimeric polypeptides and methods of use thereof
WO2017151940A3 (en) T-cell modulatory multimeric polypeptides and methods of use thereof
PH12018501280A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
EA202090471A1 (en) MODULATING T-CELLS MULTI-DIMENSIONAL POLYPEPTIDES AND WAYS OF THEIR APPLICATION
MX2023001119A (en) Enzyme variants and polynucleotides encoding the same.
MX2023007211A (en) Anti-myostatin antibodies and methods of use.
MX2023001834A (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use.
UA120917C2 (en) Factor viii chimeric proteins and uses thereof
MX2022011180A (en) Binding-triggered transcriptional switches and methods of use thereof.
NZ629394A (en) Synthetic brassica-derived chloroplast transit peptides
BR112015023431A2 (en) bispecific fc molecules
EA201691811A1 (en) OPTIONS GRFD AND METHODS OF THEIR APPLICATION
MX2017004559A (en) T cell receptors.
WO2016046234A3 (en) Recombinant phe-free proteins for use in the treatment of phenylketonuria
BR112015003724A2 (en) isolated polypeptide, composition, use of a composition, isolated polynucleotide, nucleic acid construct or expression vector, recombinant host cell, and methods of producing a polypeptide and producing a protein.
WO2016130628A8 (en) Griffithsin mutants
MX2010009071A (en) Isolated peptides having phospholipase inhibitory activity.
MX2015012281A (en) Improved tnf binding proteins.
EA201991195A1 (en) MULTI-DIMENSIONAL POLYPEPTIDES MODULATING T-CELLS AND WAYS OF THEIR APPLICATION
WO2013138259A3 (en) Polypeptides for treating and/or limiting influenza infection
EA202092065A1 (en) EXPRESSION OF PNEUMOCOCCAL SURFACE PROTEIN A (PspA)
PH12017500430A1 (en) Solubilized enzyme and uses thereof
CU20220017A7 (en) N-TERMINAL EXTENSION SEQUENCE FOR THE EXPRESSION OF RECOMBINANT THERAPEUTIC PEPTIDES